1:31 PM
 | 
Nov 10, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cognition's CT1812 well tolerated in Phase Ib/IIa trial for AD

Cognition Therapeutics Inc. (Pittsburgh, Pa.) reported data from the Phase Ib/IIa COG0102 trial in 19 patients with mild to moderate Alzheimer’s disease showing that all 3 doses of CT1812 were well tolerated with no serious adverse events reported. The company said cognitive...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >